|
[Related PubMed/MEDLINE]
Total Number of Papers: 52
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
A Case Report of Concurrent Graves' Disease and Subacute Thyroiditis Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome (ASIA). |
ASIA, SAT, US |
| 2 |
2022 |
A hypothyroid mother after subtotal thyroidectomy delivered a newborn with hyperthyroidism from fetal stage: a case report. |
--- |
| 3 |
2022 |
Comprehensive Analysis of lncRNA Expression Profile and the Potential Role of ENST00000604491 in Graves' Disease. |
FOXP1, GD, IKZF3, lncRNAs, PBMCs, ROC |
| 4 |
2022 |
Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment. |
--- |
| 5 |
2022 |
Stability of Anti-thyroid Stimulating Hormone Receptor Antibody in Whole Blood and Serum: Caution Required for Reflective and Batch Testing. |
--- |
| 6 |
2022 |
Timing of Graves' Hyperthyroidism Management in Pregnant Women: Impact on the Infant Thyroid Volume. |
ATDs, GD |
| 7 |
2022 |
Utility of Antibodies in the Diagnoses of Thyroid Diseases: A Review Article. |
Anti-TPO antibodies, CTLA, GD, HLA, HT, TPO, TSGT |
| 8 |
2022 |
Utility of TSH Receptor Antibodies in the Differential Diagnosis of Hyperthyroidism in Clinical Practice. |
GD, NGD, ROC |
| 9 |
2021 |
A Neonate with a Diagnosis of Pontocerebellar Hypoplasia Type 6 Treated with Biotin and Developed Biotin Interference with Laboratory Thyroid Function Tests. |
PCH6 |
| 10 |
2021 |
Clinical Course of Euthyroid Subjects With Positive TSH Receptor Antibody: How Often Does Graves' Disease Develop? |
GD |
| 11 |
2021 |
Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole. |
AIT, GD, GO, HS, ROC, TSI |
| 12 |
2021 |
Hemodynamic Instability during Thyroidectomy in Graves' Disease. |
ATDs, GD |
| 13 |
2021 |
Local immune microenvironment of skin may play an important role in the development of pretibial myxedema. |
GD, iSALT, PTM, TSHR |
| 14 |
2021 |
Serum thyroid-stimulating hormone receptor antibody levels and thyroid dysfunction after hysterosalpingography: a case-control study. |
HSG |
| 15 |
2021 |
The association between serum adenosine deaminase levels and Graves' disease. |
ADA, GD, HC, TPOAb, TSH |
| 16 |
2020 |
A case report of thyroid-associated Orbitopathy with elevated TPO antibodies. |
anti-TPO, GD, HT, TAO |
| 17 |
2020 |
A prospective randomized controlled clinical trial of Pingmu Decoction combined with acupuncture in the treatment of non-active thyroid-related ophthalmopathy. |
ebm, TSH |
| 18 |
2020 |
Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays. |
AMR, FAS, GD, TSHR |
| 19 |
2020 |
Fetal goiter identified in a pregnant woman with triiodothyronine-predominant graves' disease: a case report. |
--- |
| 20 |
2020 |
Management of thyrotoxicosis during pregnancy. |
ATD |
| 21 |
2020 |
New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report. |
ICIs, irAEs, TSAb |
| 22 |
2019 |
A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient. |
anti-PD-1, GD |
| 23 |
2019 |
Analysis in Choroidal Thickness in Patients with Graves' Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography. |
CAS, CT, GD, GO, SD-OCT, TSH |
| 24 |
2019 |
Comparison of the New, Rapid, and Fully Automated Kryptor TSH receptor Antibodies Assay (B.R.A.H.M.S.) with the Radioimmunological Assay (B.R.A.H.M.S.). |
--- |
| 25 |
2019 |
Reduced Retinal Microvascular Density Related to Activity Status and Serum Antibodies in Patients with Graves' Ophthalmopathy. |
CAS, GO, OCTA, RCD, TAZ |
| 26 |
2019 |
Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs. |
ATD |
| 27 |
2018 |
Study of Deiodinase Type 2 Polymorphisms in Graves' Disease and Ophthalmopathy in a Swedish Population. |
DIO2, FT3, FT4, GD, GO, SNPs, TPOAb |
| 28 |
2017 |
Analytical and Clinical Validation of Two Commercially Available Immunoassays Used in the Detection of TSHR Antibodies. |
hCG, TSHR, TSI |
| 29 |
2017 |
Prediction of thyroidal 131I effective half-life in patients with Graves' disease. |
ADP, RAIU, Teff |
| 30 |
2017 |
Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb. |
CT |
| 31 |
2016 |
Is modified clinical activity score an accurate indicator of diplopia progression in Graves' orbitopathy patients? |
CAS, EOM, GO |
| 32 |
2016 |
Management of Fetal and Neonatal Graves' Disease. |
ATD |
| 33 |
2015 |
Correlation of normal thyroid ultrasonography with thyroid tests. |
FT4, TgAb, TPOAb, TSH, US |
| 34 |
2015 |
Synergistic combined effect between CD40-1C>T and CTLA-4+6230G>A polymorphisms in Graves' disease. |
GD |
| 35 |
2014 |
Autoimmunity and pulmonary hypertension in patients with Graves' disease. |
PVR |
| 36 |
2014 |
Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. |
ATD |
| 37 |
2014 |
Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report. |
APS, GD, RTX, T1DM |
| 38 |
2014 |
There is no elevation of immunoglobulin e levels in Albanian patients with autoimmune thyroid diseases. |
ATD, IgE |
| 39 |
2013 |
Antenatal management of recurrent fetal goitrous hyperthyroidism associated with fetal cardiac failure in a pregnant woman with persistent high levels of thyroid-stimulating hormone receptor antibody after ablative therapy. |
--- |
| 40 |
2012 |
[Association of TNF-alpha gene polymorphisms with Graves disease susceptibility and early course thyroid stimulating hormone receptor antibody level in Chinese Han population in Anhui region]. |
GD, TNF-alpha |
| 41 |
2011 |
A genome-wide association study identifies two new risk loci for Graves' disease. |
--- |
| 42 |
2010 |
Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. |
--- |
| 43 |
2010 |
Thyroid hormones, their carrier proteins, and thyroid antibodies in the pleural effusion of two patients with graves' disease-induced thyrotoxicosis. |
ALB, TBG, TBPA |
| 44 |
2008 |
Age influences the severity of Graves' ophthalmopathy. |
--- |
| 45 |
2008 |
No association between Fas A/G polymorphism and therapeutic effects induced by methimazole treatment for Graves' disease in Northern Chinese. |
GD, MMI |
| 46 |
2005 |
Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease. |
GD, SLE, TPO |
| 47 |
2005 |
Elevation of serum adiponectin levels in Basedow disease. |
--- |
| 48 |
2005 |
Evaluation of management of Graves' disease in District General Hospital: achievement of consensus guidelines. |
--- |
| 49 |
2003 |
[Significance of combining tests of thyroid autoantibodies in differential diagnosis between Graves's disease and Hashimoto's hyperthyroidism]. |
FNB, sTSH, TGA, TMA, TPOAb |
| 50 |
2000 |
[Neonatal hyperthyroidism in a premature infant born to a mother with Grave's disease]. |
--- |
| 51 |
1994 |
Clinical evaluation of biotin-binding immunoglobulin in patients with Graves' disease. |
BBI, MCAb, TgAb |
| 52 |
1993 |
Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose. |
ATD, GD |
|
A Search Service for Abbreviation / Long Form
